Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Royal Society targets £20m for early-stage tech support

This article was originally published in Clinica

Executive Summary

The UK's Royal Society has launched an Enterprise Fund (RSEF) aimed at supporting innovation "by investing in early-stage business opportunities founded on outstanding technology". The fund, which is said to have already attracted donations amounting to “several million pounds", will focus on what the Royal Society sees as a gap in early-stage investments in the £0.25-2m ($0.37-3m) range. Marking its 350th anniversary campaign, it is aiming to capitalise the fund initially to around £20m. The Society sees "three key gaps within the UK innovation environment", namely: a funding gap for early-stage investments, in the said range; a "preparedness gap", with early-stage science-based projects "not always ready to go to the market for financing"; and a research area gap, with "comparatively poor funding" of non-medical research fields.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel